On December 19, 2023, CymaBay Therapeutics, Inc. and Lewis Stuart, the company?s Chief Commercial Officer, mutually agreed that Mr. Stuart will cease to be an officer and employee of CymaBay effective December 29, 2023. Mr. Stuart will be entitled to severance in accordance with his Offer Letter dated March 24, 2021. Ben Kozub, VP Liver Franchise Lead, will assume leadership of the commercial organization effective immediately.

Mr. Kozub joined CymaBay in November 2020 and has been integral in the company?s pre-commercial planning to date.